Bayer

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.
Gebruikersavatar
Banner
Premiummember
Premiummember
Berichten: 1957
Lid geworden op: 19 feb 2015 09:29
waarderingen: 1152
Contacteer:

Re: Bayer

Bericht door Banner »

charel01 liked last!



Volg Beursig.com op Twitter en Facebook

     


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 677
Lid geworden op: 30 mei 2018 21:25
waarderingen: 269
Contacteer:

Re: Bayer

Bericht door And its gone! »

BRIEF-Bayer Reaches Deals On Big Share Of 125,000 Roundup Weedkiller Suits - Bloomberg News
07:13 (25/05) - Bron: Reuters
May 25 (Reuters) -
* BAYER REACHES DEALS ON BIG SHARE OF 125,000 ROUNDUP
WEEDKILLER
SUITS - BLOOMBERG NEWS, CITING SOURCES
* BAYER IS LIKELY TO ANNOUNCE SETTLEMENTS, WHICH NEED
APPROVAL
FROM COMPANY’S SUPERVISORY BOARD, IN JUNE - BLOOMBERG NEWS

Source text: https://bloom.bg/3d19qFJ
Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))
charel01 liked last!
GOOGL, BAYN, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 677
Lid geworden op: 30 mei 2018 21:25
waarderingen: 269
Contacteer:

Re: Bayer

Bericht door And its gone! »

Bayer has verbal agreement with some glyphosate claimants- Bloomberg
08:43 (25/05) - Bron: Reuters
FRANKFURT, May 25 (Reuters) - Bayer BAYGn.DE said on
Monday it had made progress seeking a settlement over claims its
glyphosate-based Roundup weedkiller causes cancer, after
Bloomberg reported the company reached a verbal agreement on
about 50,000 to 85,000 cases.
Bloomberg cited people familiar with the negotiations as
saying that the deals have yet to be signed and Bayer is likely
to announce the settlements in June.
"We've made progress in the Roundup mediation discussions
under the auspices of Ken Feinberg, but in keeping with the
confidentiality of this process, the company will not speculate
about settlement outcomes or timing," a Bayer spokesman said.
Bloomberg reported the overall number of U.S. cancer
lawsuits stood at 125,000, including tens of thousands being
held in abeyance by plaintiffs' lawyers under agreements with
Bayer.
Bayer said in April it has been served with cases in court
from 52,500 U.S. plaintiffs who blame Roundup and other
glyphosate-based weedkillers for their cancer, up from 48,600 in
February.

(Reporting by Ludwig Burger; editing by Thomas Seythal)
((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
charel01 liked last!
GOOGL, BAYN, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 23830
Lid geworden op: 02 jan 2012 20:17
Locatie: Provincie Antwerpen
waarderingen: 12492
Contacteer:

Re: Bayer

Bericht door charel01 »

Friday - May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer

Berlin, May 22, 2020 – Bayer has submitted an application for marketing authorization for its precision oncology treatment larotrectinib to the Ministry of Health, Labor and Welfare (MHLW) in Japan. Larotrectinib is an oral TRK inhibitor that has been developed specifically to treat adults and children with locally advanced or metastatic solid tumors that have the rare genomic alteration called a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. The product is already approved in several countries under the brand name Vitrakvi™, including the U.S., Brazil, Canada and countries of the European Union (EU). Filings in other regions are underway or planned.

“With this submission, we are one step closer to providing patients and physicians in Japan with a highly selective treatment exclusively designed for adults and children with TRK fusion cancer, that has the potential to significantly improve treatment outcomes regardless of tumor type or patient age,” said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer's Pharmaceutical Division. “While cancers have previously been treated mainly in the body, larotrectinib was developed specifically to treat patients with TRK fusion cancer, regardless of where in the body the tumor originates. Larotrectinib represents an important advancement in the fight against this rare cancer, as it could replace costly treatment that is not targeted specifically to this cancer and does not have proven efficacy and safety in this patient population.”

The submission to the MHLW is based on clinical trial data from the Phase I trial of adult patients, the Phase II NAVIGATE trial in adult and adolescent patients and the Phase I/II pediatric SCOUT trial. In these trials, larotrectinib was investigated across more than 20 different histologies of solid tumors including lung, thyroid, melanoma, gastrointestinal stromal tumors, colon, cholangiocarcinoma, soft tissue sarcomas, salivary gland and infantile fibrosarcoma.

TRK fusion cancer is rare overall. It affects both children and adults and occurs in varying frequencies across various tumor types. TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing an altered TRK protein. The altered protein, or TRK fusion protein, becomes constitutively active or overexpressed, triggering the activation of an intercellular signaling cascade. These TRK fusion proteins act as oncogenic drivers that fuel the spread and growth of the patients’ cancer, regardless of where it originates in the body.

About larotrectinib
Larotrectinib, a specific oral TRK inhibitor, was exclusively designed to treat tumors that have an NTRK gene fusion. The compound has demonstrated high response rates and durable responses with a favorable safety profile over three years in adults and children with TRK fusion cancer, including central nervous system (CNS) tumors. It has the largest dataset and longest follow-up data of any TRK inhibitor. The trials are still ongoing, with the latest dataset published in The Lancet Oncology and additional updates planned to be presented at upcoming scientific meetings.

Larotrectinib was approved in September 2019 in the European Union under the brand name Vitrakvi™ for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. Vitrakvi has also received regulatory approval in additional markets, including the U.S, Brazil and Canada. Filings in other regions are underway or planned.

Following the acquisition of Loxo Oncology by Eli Lilly and Company in February 2019, Bayer has obtained the exclusive licensing rights for the global development and commercialization, including in the U.S., for larotrectinib and the investigational another TRK inhibitor selitrectinib (BAY 2731954) progressing through clinical development.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development.
Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Find more information at www.pharma.bayer.com
Go with the flow.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 677
Lid geworden op: 30 mei 2018 21:25
waarderingen: 269
Contacteer:

Re: Bayer

Bericht door And its gone! »

UPDATE 2-Bayer settles Roundup cancer lawsuits for up to $10.9 billion
19:12 (24/06) - Bron: Reuters
(Adds background on events leading up to settlement)
By Ludwig Burger
FRANKFURT, June 24 (Reuters) - Bayer AG BAYGn.DE agreed to
pay as much as $10.9 billion to settle thousands of U.S.
lawsuits claiming that its widely-used weedkiller Roundup caused
cancer after more than a year of talks, resolving litigation
that has pummeled the company's share price.
The German drugs and pesticides maker has come to terms with
about 75% of the 125,000 filed and unfiled claims overall, it
said in a statement on Wednesday of the deal to end legal
disputes it inherited with its $63 billion takeover of Monsanto
in 2018.
The settled cases over Roundup and other glyphosate-based
weedkillers account for about 95% of those currently set for
trial, it added.
"The Roundup settlement is the right action at the right
time for Bayer to bring a long period of uncertainty to an end,"
Bayer Chief Executive Werner Baumann said.
The company said it will make a payment of $8.8 billion to
$9.6 billion to resolve the current Roundup litigation -
including an allowance expected to cover unresolved claims - and
$1.25 billion to support a separate class agreement to address
potential future litigation.
Bayer said in February it did not need to write down
Monsanto's value in its books if it has to spend $10 billion on
a settlement, reflecting the average analyst estimate at the
time.
The company, whose management in April regained shareholder
support for its handling of the litigation process, has denied
claims that Roundup or its active ingredient glyphosate causes
cancer, saying decades of independent studies have shown the
product is safe for human use.
Monsanto began selling Roundup in 1974, and while the
formulation is no longer patent protected, Roundup remains
widely available.
Bayer has repeatedly said Roundup is safe and important to
farmers who use the herbicide in combination with the company's
genetically modified seeds.


(Reporting by Ludwig Burger; Editing by Edward Taylor, Maria
Sheahan and Bill Berkrot)
((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))
Op naar de 100€ 8-)
Chukky2 liked last!
GOOGL, BAYN, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie